https://doi.org/10.55788/2cdaf94c
In this podcast (09:36) we’re diving into highlights from the European Association of Dermatology and Venereology, or EADV, Annual Meeting held in Amsterdam, the Netherlands from 25 to 28 September 2024. In this episode, we’ll cover 6 key sessions that focus on advances in dermatology. You could say we've got skin in the game when it comes to bringing you the latest dermatology research!
- Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
- IL-13 inhibitor shows safety and efficacy in AD over 3 years
- Deuruxolitinib significantly improves hair satisfaction in alopecia areata
- Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
- soBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
- Prurigo nodularis: long-term treatment reduces relapse events
Posted on
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
News in Atopic Dermatitis
3-Year results highlight durable effects of IL-13 inhibitor in AD
IL-22RA1 inhibition shows potential in atopic dermatitis
Lifelong psychosocial burden linked to early-onset atopic dermatitis
Second-generation selective PDE4 inhibitor shows promise in AD
What’s New in Prurigo Nodularis and Lichen Planopilaris
Prurigo nodularis: long-term treatment decreases relapse events
JAK1 inhibitor shows promising long-term efficacy in PN
Hand Eczema: End of the Therapeutic Draught
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
Hidradenitis Suppurativa: New Medications on the Horizon
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Bimekizumab shows sustained 2-year efficacy in hidradenitis suppurativa
Familial hidradenitis suppurativa tied to metabolic disease
Psoriasis in 2024
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
A new era of care: Artificial intelligence in psoriasis
New Developments in Hair Disorders
Deuruxolitinib significantly improves hair satisfaction in AA
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Miscellaneous
Vitiligo: Prolonged facial re-pigmentation maintained with continued ruxolitinib cream
Anti-KIT antibody: the next frontier in CSU treatment?
New targets identified for acute and chronic wound healing
Interesting Posters
PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis
Semaglutide improves outcomes for patients with obesity and HS
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com